Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables

NCT07012148 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07012148
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07012148 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FORESITE (FOREcasting Seizures to Initiate ThErapy): Optimizing Management of Drug-Resistant Epilepsy Using Seizure Forecasts Via Subscalp EEG and Wearables
Lead sponsor
Mayo Clinic
Phase
Phase 1
Overall status
Recruiting
Start date
January 20, 2026
Completion date
December 31, 2029
Enrollment
12 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

drug refractory epilepsy, focal epilepsy, generalized seizure